**FHL2 expression and variants in hypertrophic cardiomyopathy**

Felix W. Friedrich · Silke Reischmann · Aileen Schwalm · Andreas Unger · Deepak Ramanujam · Julia Münch · Oliver J. Müller · Christian Hengstenberg · Enrique Galve · Philippe Charron · Wolfgang A. Linke · Stefan Engelhardt · Monica Patten · Pascale Richard · Jolanda van der Velden · Thomas Eschenhagen · Richard Isnard · Lucie Carrier

Received: 22 May 2014 / Revised: 4 October 2014 / Accepted: 22 October 2014 / Published online: 31 October 2014
© The Author(s) 2014. This article is published with open access at Springerlink.com

**Abstract** Based on evidence that FHL2 (four and a half LIM domains protein 2) negatively regulates cardiac hypertrophy we tested whether FHL2 altered expression or variants could be associated with hypertrophic cardiomyopathy (HCM). HCM is a myocardial disease characterized by left ventricular hypertrophy, diastolic dysfunction and increased interstitial fibrosis and is mainly caused by mutations in genes coding for sarcomeric proteins. FHL2 mRNA level, FHL2 protein level and I-band-binding density were lower in HCM patients than control individuals. Screening of 121 HCM patients without mutations in established disease genes identified 2 novel (T171M, V187L) and 4 known (R177Q, N226N, D268D, P273P) FHL2 variants in unrelated HCM families. We assessed the structural and functional consequences of the nonsynonymous substitutions after adeno-associated viral-mediated gene transfer in cardiac myocytes and in 3D-engineered heart tissue (EHT). Overexpression of FHL2 wild type or nonsynonymous substitutions in cardiac myocytes markedly down-regulated α-skeletal actin and partially blunted hypertrophy induced by phenylephrine or endothelin-1. After gene transfer in EHTs, force and velocity of both contraction and relaxation were higher with T171M and V187L FHL2 variants than wild type under basal conditions. Finally, chronic phenylephrine stimulation depressed EHT function in all groups, but to a lower extent in

**Electronic supplementary material** The online version of this article (doi:10.1007/s00395-014-0451-8) contains supplementary material, which is available to authorized users.

F. W. Friedrich · S. Reischmann · A. Schwalm · T. Eschenhagen · L. Carrier
Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
E-mail: l.carrier@uke.de; f.friedrich@uke.de

F. W. Friedrich · S. Reischmann · A. Schwalm · T. Eschenhagen · L. Carrier
DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Hamburg, Germany

A. Unger · W. A. Linke
Department of Cardiovascular Physiology, Ruhr University Bochum, Bochum, Germany

D. Ramanujam · S. Engelhardt
Institute of Pharmacology and Toxicology, Technical University Munich, Munich, Germany

D. Ramanujam · S. Engelhardt
DZHK (German Centre for Cardiovascular Research), partner site Munich, Munich, Germany

J. Münch · M. Patten
University Heart Center Hamburg, Hamburg, Germany

O. J. Müller
Department of Cardiology, Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany

O. J. Müller
DZHK (German Centre for Cardiovascular Research), partner site Heidelberg/Mannheim, Heidelberg, Germany

Present Address:
C. Hengstenberg
German Heart Centre of the Technical University Munich, Munich, Germany

C. Hengstenberg
Klinik und Poliklinik für Innere Medizin II, Universitätsklinikum Regensburg, Regensburg, Germany

E. Galve
Unitat d’Insuficiència Cardiaca, Servei de Cardiologia, Hospital Vall d’Hebron, Barcelona, Spain
T171M-transduced EHTs. These data suggest that (1) FHL2 is down-regulated in HCM, (2) both FHL2 wild type and variants partially protected phenylephrine- or endothelin-1-induced hypertrophy in cardiac myocytes, and (3) FHL2 T171M and V187L nonsynonymous variants induced altered EHT contractility. These findings provide evidence that the 2 novel FHL2 variants could increase cardiac function in HCM.

Keywords Hypertrophic cardiomyopathy · Hypertrophy · FHL2 · Engineered heart tissue · Hypercontractility

Introduction

The family of four and a half LIM (FHL) proteins is composed of FHL1–4, ACT (activator of CREM) and ARA55, and is characterized by an N-terminal half LIM domain followed by four complete LIM domains [12, 30]. FHL proteins are components of adhesion complexes, can act as transmitters of Rho signaling pathways and are involved in tissue-specific gene regulation [5, 39, 47, 60]. The second member, FHL2 plays a role in cell cycle regulation, differentiation and apoptosis, assembly of extracellular matrix, bone formation, and wound healing (for review, see [30]). FHL2 is highly expressed in the heart throughout embryonic development and in adults [13, 32]. FHL2 has been first shown to be located in the Z-disk and to a lesser extent in the M-band of the sarcomere in neonatal rat cardiac myocytes (NRCMs) [50] and further analysis indicated I-band localization in papillary muscle [33]. It interacts with several components, particularly with titin in the cardiac-specific N2B domain (I-band) and the IS2 region (M-band), where it couples cardiac metabolic enzymes to sites of high energy consumption [33]. A body of evidence indicates that FHL2 inhibits cardiac hypertrophic pathways, such as calcineurin–NFAT (nuclear factor of activated T cells)-dependent gene expression via binding of calcineurin [28], or the MEK1–ERK1/2 signaling cascade by binding to ERK2 [44]. Additionally, FHL2 inhibited serum response factor (SRF)-dependent transcription in a Rho-dependent manner in embryonic stem cells and heart [42]. FHL2 deficient mice exhibited normal response to short-term TAC [11], but developed exaggerated cardiac hypertrophy under chronic isoprenaline stimulation [32], suggesting that the implication of FHL2 in heart failure depends on the trigger inducing heart failure. Whereas it was reported that FHL2 is up-regulated upon adrenergic stimulation in vivo in rodents [28], FHL2 protein abundance was markedly reduced in angiotensin II (AngII)-induced cardiac hypertrophy in mice [40] and in human heart failure [4]. Integrating the predominantly heart-specific expression of FHL2, its suggested antihypertrophic role and its lower expression in human heart failure, we hypothesized that FHL2 altered expression or genetic variants could be associated with HCM. HCM is the most prevalent myocardial disease (1:500; [17]). Its hallmarks are hypertrophy, predominantly in the interventricular septum, diastolic dysfunction, myocardial fibrosis and disarray. The phenotype is very variable, and diastolic dysfunction can be the first feature of the disease. Symptoms include dyspnea, chest pain, palpitations, lightheadedness, fatigue, and syncope. HCM is a leading cause of sudden cardiac death (SCD) in young athletes and is connected with a significant risk of heart failure [24, 34]. HCM is a genetic disease mainly transmitted as an autosomal dominant trait. It is caused by mutations in at least 14 genes coding for sarcomeric components (for reviews, see [20, 45, 49, 51]). More recently, mutations in FHL1 have been shown to be associated with HCM [21]. We evaluated FHL2 expression in patients and mouse models of HCM and screened the FHL2 gene for genetic variants in a cohort of HCM patients devoid of mutations in established disease genes. We identified six FHL2 genetic variants and analyzed the molecular and/or functional impact of the nonsynonymous substitutions after gene transfer in rat cardiac myocytes and engineered heart tissues (EHTs).

Methods

A detailed description of materials and methods can be found in the Supplemental Material.

Patients and human samples

We enrolled 121 HCM index cases without mutations in MYH7, MYBPC3, TNNT2, TNNI3, or MYL2 (data not
shown). They were selected out of 299 HCM index cases recruited from the Eurogene Heart Failure cohort supported by the Leducq Foundation [19, 21]. Diagnosis was grounded on medical history, physical examination, electrocardiogram, and echocardiogram (left ventricle (LV) wall thickness ≥15 mm in probands and >13 mm in relatives) [8–10]. Controls consisted of 262 individuals.

Human myocardial samples were obtained from HCM patients who underwent septal myectomy or heart transplantation, from a patient undergoing aortic valve implantation due to aortic stenosis, and from individuals who had no cardiac disease but died of another cause. All materials from patients and controls were taken with informed consent of the donors and with approval of the local ethical boards.

Mouse models

The study complies with the Guide for the Care and Use of Laboratory Animals published by the NIH (Publication No. 85–23, revised 1985). Mybpc3-targeted knock-out (KO) and knock-in (KI) mice were developed previously and maintained on the Black swiss genetic background [6, 59].

Pre-embedding immunoelectron microscopy

Human septal myectomy and mouse ventricular tissues used for the study were fixed in 4 % paraformaldehyde, 15 % saturated picric acid in 0.1 M phosphate buffer (PB) pH 7.4 overnight at 4 °C. Sections were cut on a vibratome (Leica VT 1000S) at a thickness of 50 μm, blocked in 20 % NGS in PBS and were incubated with FHL2 (Abcam 12327) primary antibody in phosphate-buffered saline (PBS) containing 5 % normal goat serum (Vector Laboratories, Burlingame, CA, USA) overnight at 4 °C. After washing in PBS, sections were incubated with 1.4-nm gold-coupled secondary antibodies (diluted 1:100 in PBS; Nanoprobes, Stony Brook, NY, USA) overnight at 4 °C. After several washings sections were postfixed in 1 % glutaraldehyde in PBS for 10 min and then incubated with HQ Silver kit (Nanoprobes). After treatment with OsO4, sections were stained with uranyl acetate, dehydrated and embedded in Durecupan resin (Fluka, Switzerland). Ultrathin sections were prepared (Ultracut S; Leica, Germany) and examined with a ZEISS 910 electron microscope.

Screening of FHL2 for genetic variants

FHL2 gene has eight exons, of which five (exons 4–8) are coding. There are four FHL2 variants mainly differing in the 5’UTR, but encoding the same isoform. Therefore, only the five coding exons for FHL2, including neighboring intron boundaries were screened by PCR amplification performed on 30 ng of genomic DNA from peripheral lymphocytes using specific primer pairs (Supplemental Table 2). Sequences were examined using Codon Code Aligner Software®. Reference FHL2 sequence was taken from NCBI (NG_008844.2) with +1 designing the A of the ATG codon.

Rat cardiac myocytes culture, transduction, and hypertrophy stimulation

Isolation of neonatal rat cardiac myocytes (NRCMs) and stimulation with hypertrophy stimuli, followed by subsequent automated cell size determination was performed as defined previously [29]. In detail, cells were transduced with adeno-associated virus serotype 6 (AAV6)-FHL2 at a MOI of 100,000, serum was reduced to 0.2 % during 24 h and then NRCMs were stimulated for 48 h with phenylephrine (PE; 50 μM), endothelin-1 (ET1; 100 nM) or DMSO (n = 3 different experiments, each in triplicates). Afterwards, cells were stained for alpha-actinin and automated cell size and number quantification were executed. For mRNA analysis, NRCMs were transduced with AAV6-FHL2 at a MOI of 30,000 (n = 5 per condition), serum was reduced to 0.2 % during 24 h and then NRCMs were stimulated for 48 h with PE (50 μM) or without. Subsequently, cells were harvested and RNA was extracted as described in the appropriate section thereafter.

Engineered heart tissue generation, transduction, contraction measurements, and immunofluorescence

Generation of EHTs from neonatal rat heart cells was performed as previously described [14, 21, 25]. EHTs were transduced with AAV6 encoding FHL2 WT or variants at a MOI of 1,000. Briefly, transduction was performed directly in the reconstitution mix before pipetting it into the agarose slots. Constructs were then cultured at 37 °C in 7 % CO2 humidified cell culture incubator for 14–21 days. EHT medium for the first 10 days of culture consisted of DMEM (Biochrom), 10 % horse serum inactivated (Gibco), 2 % chick embryo extract, 1 % penicillin/streptomycin (Gibco), insulin (10 μg/mL, Sigma-Aldrich), and aprotinin (33 μg/mL, Sigma-Aldrich). To exclude any hypertrophic influence by the serum we applied a protocol with horse serum content being successively replaced by triiodothyronine (T3) and hydrocortisone after day ten of culture [26]. Therefore, horse serum medium content was reduced to 4 % between day 10 and 13. Up to day 13 medium was changed three times per week, afterwards twice daily. From day 13 onwards EHTs were kept in serum-free medium, i.e. the above medium without horse serum plus T3 (0.5 ng/mL, European Commission-Joint Research Centre IRMM-469) and low concentrations of
hydrocortisone (50 ng/mL, Sigma-Aldrich). EHTs started to beat coherently one week after casting. For chronic PE stimulation, phenylephrine (PE, 20 μM, powder dissolved in H2O) was added to the medium every 12 h for seven consecutive days starting day 14. Contraction measurements were performed on day 8, 10, 13, 14, 17, 20 and 21 as previously described [14, 21, 25, 48]. Subsequently after chronic stimulation, EHTs were PBS washed three times and directly processed or frozen in liquid nitrogen.

For immunofluorescence analysis, the entire EHTs were analyzed using confocal imaging as specified [21]. Immunofluorescence was performed as described above (primary antibodies against FLAG 1:800 and cMyBP-C, custom 1:200, nuclear staining by Draq5, Axxor, 1:1000).

Statistical analysis

Data are presented as mean ± SEM. Statistical analyses were performed by one-way or two-way ANOVA followed by Dunnett’s or Bonferroni’s post test, and by Student’s t test as indicated in the figure legends, using the GraphPad software (GraphPad Software), version 5.02. A value of P < 0.05 was considered significant. Quantitative PCR data analyses were carried out using the ΔΔCt method.

Results

Reduction of FHL2 expression and I-band binding signal in human and mouse HCM tissue

It has been shown that FHL2 protein level is markedly reduced in human failing hearts [4]. To examine whether FHL2 expression is altered in HCM we measured both mRNA and protein levels in ventricular tissue of HCM patients carrying MYBPC3 mutations [52]. FHL2 mRNA and FHL2 protein levels were >50 % lower in HCM patients than in controls (Fig. 1a, d, e). Similarly, FHL2 mRNA levels were markedly reduced in two HCM mouse models, the homozygous Mybpc3-targeted knock-in (Hom-KI) [59], and both heterozygous (Het-KO) and homozygous (Hom-KO) Mybpc3-targeted knock-out mice (Fig. 1b, c; [6]). Moreover, whereas no difference was observed in the right ventricle between WT, Het-KO and Hom-KO, FHL2 mRNA level was lower merely in the hypertrophied parts of the Het-KO (=septum) and Hom-KO (=septum + LV; Online Fig. 1).

We then investigated the subcellular localization of FHL2 by immunogold labeling in cardiac myofibres on ultrathin sections of ventricular tissue obtained from of a human donor, a patient with aortic stenosis, two HCM patients with a MYBPC3 mutation, and from WT and Hom-KI mice (Fig. 1f–k). The highest density of immunogold particles for FHL2 was observed in the middle of the I-band (inserts, higher magnification, Fig. 1f–k), suggesting that most of the cytosolic FHL2 is bound to the spring region of titin. Some immunolabelling was also observed in the cytosol, but the density of the enhanced gold particles was consistently lower than in the I-band. Overall, the abundance of gold particles was ~50 % lower in HCM and Hom-KI cardiac sections than in donor tissue.

Identification of FHL2 genetic variants in patients with HCM

Next we evaluated whether FHL2 genetic variants could be associated with HCM. We screened a cohort of 121 HCM patients devoid of mutations in five of the major HCM disease genes (MYH7, MYBPC3, TNNT2, TNNI3, or MYL2). We identified two novel and one known FHL2 genetic variants and three other known FHL2 synonymous polymorphisms (Fig. 2; Table 1, Online Table 1).

Variant I is a c.530G>A transition in exon 7 (p.Arg177Gln (R177Q)), which affects the LIM 3 domain. It was detected in three individuals of a French family (F-19949). The index patient (III.3) was diagnosed with HCM at the age of 13. Heart transplantation was required at the age of 19 because of congestive heart failure with pulmonary edema. Variant I was found in 2/262 control individuals and in 201 of 12,805 alleles (1.5 %; rs1131188481) in the NHLBI Exome variant server (http://evs.gs.washington.edu/EVS/), a freely available database comprising about 13,006 alleles of European American and African American populations. In silico analysis using the prediction programs Mutation Taster (http://www.mutationtaster.org) and PolyPhen-2 (http://genetics.bwh. 
Harvard.edu/pph2) classified variant I as a benign polymorphism (rs1131188481).

Variant II is a c.512C>T transition in exon 7, which results in the exchange of a threonine with a methionine at position 171 in the third LIM domain (p.Thr171Met (T171M)). This nonsynonymous substitution was found in a female index patient from Spain (F-19170, II.7) with a wall thickness of 22 mm. The father of the proband (I.1) died at the age of 79 years of stroke and the mother (I.2) passed away in the course of an acute coronary syndrome at the age of 78 years. One of the sisters (II.4) and her son (III.2) presented with HCM and received an implantable.
cardioverter defibrillator (ICD). One grandchild (V.1) also presented with HCM. One son (III.6) was positive for the variant and had earlier been diagnosed with HCM, requiring ICD implantation. He died of SCD in February 2011. The second son (III.5) also presented with HCM and received an ICD. Several affected individuals of family 19170 were not available for molecular diagnosis, which reduced the power of the co-segregation analysis. In addition, the husband of individual II.7 (II.8) also presented with HCM but does not carry the variant; he also does not have any variant in

---

Fig. 2 FHL2 genetic variants detected in patients with hypertrophic cardiomyopathy. a Pedigrees of families with HCM carrying FHL2 missense variants. Roman numerals symbolize generations. Arabic numerals mark individuals within each generation. Males are symbolized as squares, females as circles. Individuals with HCM are indicated by black symbols, individuals with an intermediate phenotype by gray symbols, unaffected individuals by empty symbols, and deceased individuals by a diagonal line. Index cases are indicated by arrows. Family members with a plus sign (+) carry the respective genetic variant at the heterozygous state; non-carriers are marked with a minus sign (−); individuals without signs were not genotyped. b Variants in the FHL2 gene. Exon numbers, and translational start (ATG) and stop (TGA) codons are indicated. Light gray squares represent noncoding regions. The FHL2 variants identified in HCM patients are depicted. c Localization of FHL2 genetic variants in the LIM domains.
Table 1 Clinical and genetic features of HCM index cases and relatives (with missense mutations)

| Family | Ind. | Sex | Birth Year | Age at diagnosis | Proband | Clinical status | Age at onset | PWth (mm) | SWth (mm) | ECG | Other symptoms | Var. | FHL2 variant | FHL2 protein consequence |
|--------|------|-----|------------|------------------|---------|-----------------|--------------|-----------|-----------|-----|---------------|------|--------------|--------------------------|
| 19949  | III.3| M   | 1984       | 18               | P       | A               | HCM age 13   | 13        | 29        | Abnormal | No            | I    | c.530G>A     | p.Arg177Gln               |
|        |      |     |            |                  |         |                 | Heart transplant age 19 |           |           |           |               |      |             |                          |
| II.2   | F    | 1959| 43         | R                | A       | n.a             | 8            | 17        | Abnormal | No            |      | c.530G>A     | p.Arg177Gln               |
| II.3   | M    | 1955| 47         | R                | NA      | n.a             | 9            | 10        | Normal   | No            |      | c.530G>A     | p.Arg177Gln               |
| III.2  | M    | 1988| 14         | R                | A       | 10              | 8            | 16        | Abnormal | Myalgia hypophonia | No | c.530G>A     | p.Arg177Gln               |
| III.1  | F    | 1997| 5          | R                | I       | n.a             | 3            | 5         | Abnormal | No            |      | c.530G>A     | p.Arg177Gln               |
| 19170  | II.7 | F   | 1942       | 66               | P       | A               | n.a          | 22        | Abnormal | NYHA II, dyspnea, angina, no subaortic obstruction | II | c.512C>T     | p.Thr171Met               |
| II.8   | M    | 1940| 70         | R                | A       | n.a             | 19           |           |           | NYHA II, pacemaker, dynamic gradient of 36 mmHg | No |              |                           |
| III.6  | M    | 1975| 19         | R                | A       | n.a             | 19           |           |           | Asymptomatic, subaortic obstruction 34 mmHg, SCD 2011 | No |              |                           |
| 20198  | II.3 | F   | 1957       | 39               | P       | A               | 28           | 16        | 20        | Abnormal Q wave, negative T wave, LVH/ Romhilt Este score 6 | III | c.559G>T     | p.Val187Leu               |
| II.1   | F    | 1954| 49         | R                | NA      | n.a             |              |           |           | Normal except LVH/ Romhilt Este score 5 | No |              |                           |
| II.2   | F    | 1956| 47         | R                | NA      | n.a             | 6            | 10        | n.a      | No            |      | c.559G>T     | p.Val187Leu               |
| I.2    | F    | 1932| 71         | R                | I       | n.a             |              |           |           | Normal except LVH/ Romhilt Este score 5 | No |              |                           |

Abnormal ECG corresponds to abnormal negative T-waves

A affected, ECG electrocardiogram, F female, HCM hypertrophic cardiomyopathy, I intermediate, Ind. individual number, LVH left ventricular hypertrophy, M male, P proband, NA not affected, n.a. not available, PWth posterior wall thickness, R relative, SCD sudden cardiac death, SWth septal wall thickness, Var. variant number
MYBPC3, MYH7, TNNT2, TNNT3, MYL2 and FHL1, suggesting that he has potentially a mutation (not yet identified) in another gene. The presence of HCM in both parents II.7 and II.7 suggests the existence of double heterozygous mutations that could explain the severity of the clinical phenotype (and SCD) of individual III.6 in one of the two children. Variant II was not detected in 262 control individuals and was not found in the NHLBI Exome variant server, indicating that it is a very rare variant (<1:1000). Mutation Taster indicates this variant to be disease causing with a probability of 99% and PolyPhen-2 envisages damaging consequences (prediction sensitivity 0.83/specificity 0.93).

Variant III is a c.559G>T transversion in exon 7, leading to a full-length mutant protein with an amino acid exchange in the third LIM domain in a highly conserved region (p.Val187Leu (V187L)). It was detected in a German patient (F-20198, II.3), presenting with a 20 mm septal wall thickness. Whereas one sister carrying the variant (II.1) was not clinically affected at the time of diagnosis, the mother (I.2) presented some LVH signs in the ECG, suggesting an intermediate phenotype. Variant III was found in 1/262 control individuals (1/524 alleles), but not in the 13,000 alleles of NHLBI Exome variant server. Like variant II, this is a very rare variant (<1:1000).

Finally, variants IV–VI were detected in the cohort but are known to be FHL2 synonymous polymorphisms (Fig. 2, Online Table 1). Variant IV is a c.678C>T transition in exon 7 (p.Asn226Asn (N226N)), which was also found in 1/262 control individuals. Frequency in the NHLBI Exome variant server is 126 in 13,328 alleles (1%; rs137869171). Variant V is a c.804C>T transition in exon 8 (p.Asp268Asp (D268D)) with a frequency of 9% in the Exome variant server (rs3087523). Variant VI is a c.819C>T transition in exon 8 (p.Pro273Pro (P273P)) with a frequency of 16% in the Exome variant server (rs11124029). Variants V and VI had already formerly been identified in healthy controls and suggested to be polymorphisms [2]. Since the three synonymous polymorphisms do not affect the amino acid sequence in contrast to the nonsynonymous variants they were not analyzed further.

FHL2 mutants do not induce cardiac myocyte hypertrophy

It has been shown that FHL2 overexpression reduced PE-induced hypertrophy in cardiac myocytes [44], suggesting an antihypertrophic role of FHL2. Therefore, we sought to evaluate whether FHL2 mutants would act differently. NRCMs were transduced with AAV6 encoding FLAG-tagged FHL2 WT or mutants, and treated with PE or ET1 for 48 h. Cell area was determined using an automated microscopic edge detection algorithm and mRNA levels of FHL2 and markers of hypertrophy were quantified by RT-qPCR (Fig. 3). Under basal conditions, cell area did not differ between the groups (Fig. 3a, b), although total FHL2 (exogenous human and endogenous rat) mRNA levels were ~two- to fourfold higher in FHL2-transduced NRCMs (Fig. 3e). To evaluate an overexpression on protein level, we used an antibody detecting the endogenous, native FHL2 directed against the N-terminal regions and an antibody only recognizing the exogenous FLAG-tagged FHL2. Staining with the FHL2 antibody revealed only one band in all samples (Fig. 3c). This suggests that the FHL2 antibody only recognized the endogenous FHL2 protein, likely because of the presence of the FLAG tag at the N-terminal end, which could hinder the binding of the FHL2 antibody. The endogenous FHL2 level did not differ significantly between the groups (Fig. 3d). We then stained the membranes with the antibody detecting the FLAG tag. Exogenous FLAG-tagged FHL2 was overexpressed in all groups (except for NT) with some slight difference (Fig. 3c, d). Due to differences in binding affinities of the antibodies no quantification of overexpression (endogenous + exogenous FHL2) was possible. Furthermore, mRNA levels of atrial natriuretic peptide (Nppa), brain natriuretic peptide (Nppb) and the NFAT-target gene regulator of calcineurin (Rcan1.4) did not differ between all groups, whereas α-skeletal actin (Acta1) mRNA levels...
were ~90% lower in FHL2-transduced than non-transduced NRCMs (Fig. 3f–i). Both PE and ET1 increased cardiac myocyte area in all groups, but to a lower extent in FHL2-transduced than non-transduced NRCMs (Fig. 3b). This was associated with a lower activation of Acta1 gene expression in FHL2-transduced NRCMs. Conversely, the PE-induced increased mRNA levels of Nppa, Nppb and Rcan1.4 did not differ between the groups, except for a partial inhibition on Rcan1.4 in T171M-transduced NRCMs (Fig. 3f–i). The amount of overexpressed FHL2 was also lower in PE-treated NRCMs. These data suggest that FHL2 WT has an antihypertrophic effect and FHL2 mutants do not lose this feature.

FHL2 mutants affect contraction parameters in rat-engineered heart tissue

Since expression of FHL2 variants did not induce an exaggerated hypertrophy after gene transfer in cardiac myocytes, we sought to evaluate whether they would affect contraction parameters of EHTs. EHTs were derived from neonatal rat heart cells, transduced or not with AAV6 encoding FHL2 WT or mutants. After 14 days of culture and transduction, EHTs were subjected to PE or control medium for 7 days. Force of contraction did not differ significantly between groups under basal conditions (no PE), although a tendency to higher force was observed in EHTs expressing T171M and V187L mutants (and *p < 0.05 vs WT using Student’s t test; Fig. 4a). Furthermore, T171M EHTs exhibited higher velocity of both contraction and relaxation than WT EHTs (and *p < 0.01 vs WT using Student’s t test; Fig. 4b–c). V187L EHTs transduced with R177Q did not differ to WT EHTs. Chronic PE stimulation reduced all parameters in WT-, R177Q- and V187L-transduced EHTs, but had a blunted effect in T171M-transduced EHTs (Fig. 4a–c). As observed in NRCMs, mRNA levels for Nppa, Nppb, Acta1 and Rcan1.4 did not differ between groups under basal conditions (Online Fig. 2). Chronic PE stimulation induced accumulation of Nppa and Nppb mRNAs in all groups, but had no major effect on Rcan1.4 mRNA level (Online Fig. 2).

Under basal conditions, total FHL2 mRNA levels were ~twofold to threefold higher in FHL2-transduced EHTs than in non-transduced EHTs, suggesting a slight overexpression (Online Fig. 3). As in NRCMs, staining with the FHL2 antibody revealed only one band in all samples (Online Fig. 3b). The endogenous FHL2 level did not differ significantly between the groups (Online Fig. 3b, c). FLAG-tagged FHL2 proteins were detected by Western blot only in FHL2-transduced EHTS, but no major difference was observed between groups (Online Fig. 3b, c). Due to differences in binding affinities of the antibodies no quantification of total (endogenous + exogenous FHL2) was possible. Immunofluorescence analysis

![Fig. 4](https://example.com/image.png)
revealed a striated pattern for FLAG-FHL2 WT, R177Q, T171M and V187L proteins, mainly in alternation with cMyBP-C doublets, but also within the cMyBP-C doublets, suggesting an additional M-band incorporation (Fig. 5).

**Discussion**

The recent evidence that FHL2 plays an antihypertrophic role and that its expression is reduced in human heart failure suggested that altered FHL2 expression or variants could be associated with HCM. Therefore, we evaluated FHL2 expression in human and mouse HCM cardiac tissue samples and screened FHL2 for genetic variants in a cohort of 121 HCM unrelated index cases, who do not carry any other known mutations in major sarcomeric genes. The key findings are as follows: (1) FHL2 expression and number of FHL2 immunogold particles were lower in ventricular tissue of HCM patients; (2) out of six identified FHL2 variants in unrelated HCM families, two were novel.

**Fig. 5** Immunofluorescence analysis of rat-engineered heart tissue transduced with FHL2 wild type or variants. EHTs were transduced with AAV6 encoding FLAG-tagged FHL2 wild type (WT) or mutants (R177Q, T171M, V187L) at a MOI of 1,000. After fixation at day 14, EHTs were stained with antibodies directed against the FLAG epitope (green) and cardiac myosin-binding protein C (cMyBP-C, red). Scale bars 10 μm.
(T171M, V187L); (3) gene transfer of FHL2 WT or nonsynonymous variants in cardiac myocytes down-regulated Acta1 and partially blunted the hypertrophic response induced by PE or ET1; (4) force and velocity of contraction or relaxation of EHTs were higher in the presence of T171M and V187L mutants than WT under basal conditions; (5) chronic PE stimulation reduced contractile force and velocities in all groups, but had no major effect in T171M-transduced EHTs. These findings support the view that FHL2 expression is negatively associated with HCM and that FHL2 WT partially protects against PE- or ET1-induced hypertrophy, whereas T171M and V187L FHL2 mutants mainly induced hypercontractility.

The molecular mechanisms by which changes in FHL2 expression and/or FHL2 variants could contribute to HCM and associated cardiac dysfunction remain elusive at this point. One obvious hypothesis is a loss of antihypertrophic function [15, 28, 40, 42, 44]. The present study shows not only a downregulation of FHL2 mRNA levels upon PE stimulation in NRCMs, but also lower FHL2 mRNA and protein levels as well as a lower number of FHL2 immunogold particles in the I-band of the sarcomere in human and mouse models of HCM. This supports previous findings of reduced FHL2 protein levels in AngII-induced cardiac hypertrophy in mice [40] and in failing human hearts [4]. Reduced FHL2 mRNA levels were also found in models of pathological hypertrophy induced by ET1, PE or afterload enhancement in rat EHT ([26] and Hirt, unpublished data). Besides a lower grade of antihypertrophic action, low FHL2 expression could also have consequences on cardiac energy metabolism [33]. Whether FHL2 downregulation is a dispensable by-product or whether the same mechanisms leading to hypertrophy and heart failure cause this concomitant downregulation is unclear. Altogether, these data suggest that FHL2 expression is negatively associated with HCM and more generally with cardiac disease.

However, several arguments suggest that the hypothesis of the lack of antihypertrophic function of FHL2 mutants is unlikely. First, FHL2 mutants showed a stable expression on gene and protein level. Second, in the absence of hypertrophic stimuli, cardiac myocyte area and mRNA levels of Nppa, Nppb and Rcan1.4 did not differ between non-transduced and FHL2-transduced NRCMs, indicating that neither FHL2 WT nor mutants exert growth effects per se. Conversely, Acta1 gene expression was markedly down-regulated after gene transfer of FHL2 WT or mutants in NRCMs, whereas downregulation of Flh2 and up-regulation of Acta1 coincided with the appearance of hypertrophy in Mybpc3-targeted KI HCM mice (Friedrich, unpublished data and [22, 35]). This supports the previously suggested role of FHL2 as a negative regulator of cardiac hypertrophy [28, 42, 44]. Finally, FHL2 mutants had similar effects as WT on cardiac myocyte area and Nppa, Nppb, Rcan1.4 and Acta1 mRNA levels, which indicates that at least in the 48 h NRCM assay the genetic variants do not interfere with the antihypertrophic activity of FHL2.

Findings in EHTs rather indicate that the genetic variants may induce hypercontractility, which suggests a gain-of-function effect. Out of the six FHL2 variants identified in HCM families, variants IV–VI are silent variants that were previously recognized as SNPs (rs137869171, rs3087523 and rs11124029), whereas variants I–III are FHL2 nonsynonymous substitutions (R177Q, T171M, V187L). These nonsynonymous substitutions were found in HCM-affected individuals, they were expressed into stable proteins, correctly incorporated into the sarcomere and thereby may act in a dominant fashion on endogenous FHL2/sarcomere function. However, there are arguments against variant I (R177Q) as disease causing. First, variant I (recently named as rs1131188481) was found in 201 of 12,805 alleles (frequency 1.5 %) in the NHLBI Exome variant server and was classified as a benign polymorphism by Mutation Taster and Polyphen-2. Second, variant I was detected in a family, which also carries a mutation in FHL1 [21]. Finally, the EHT contractile parameters did not differ to WT under basal conditions and after chronic PE. In contrast, the novel FHL2 variants (T171M, V187L) could be associated with or contribute to HCM for the following reasons. First, variants II and III were not detected in the large cohort of the NHLBI Exome variant server and in silico analysis predicts harmful consequences for variant I. Second, the expression of both variants in EHT induced hypercontractility, characterized by either higher amplitude and/or shorter kinetics of force under basal conditions. Additionally, whereas chronic PE stimulation depressed EHT force of contraction in all groups as expected, it did not have any effect in T171M-transduced EHTs. One explanation could be that the T171M substitution alters post-translational modifications such as phosphorylation or oxidation. In fact, in silico analysis proposes a phosphorylation of FHL2 at position T171 (http://www.phosida.com). Which kinase performs this modification is unknown, but ERK2 and protein kinase D were previously excluded [44, 54]. Hypercontractility with consecutive higher LV systolic pressure is a common finding in patients with HCM [23, 41] and is in agreement with previous findings obtained for HCM-associated FHL1 and ANKRD1 variants in EHTs [14, 21]. It is also consistent with the increased myofilament Ca2+ sensitivity observed in human or mouse models of HCM with different sarcomere gene mutations [18, 31, 37, 38, 46, 57, 58], and with enhanced contractile function in muscle fibers, cardiac myofibrils, or cardiac myosins containing different MYH7-HCM mutations and HCM mouse native or engineered tissues [1, 3, 7].
37, 43, 53, 55]. Hypercontractility and diastolic dysfunction, but not LVH have also been observed in a transgenic Tnni2 HCM mouse model [56]. Similarly, functional changes (such as increased myofilament Ca\(^{2+}\) sensitivity, diastolic dysfunction) do exist without hypertrophy in heterozygous Mybp3\(^{-}\)-targeted KI mice [18, 22, 55]. These data support the findings in human HCM patients who exhibited “supranormal” contractile function or diastolic dysfunction without accompanying LVH [16, 27, 36]. Hence, changes in contractility as induced by FHL2 variants could precede or may even be independent of LVH development and consistent with the conception that compensatory mechanisms may play a role in the development of hypertrophy.

In conclusion, this study provides evidence for altered FHL2 expression and novel FHL2 genetic variants in HCM. However, whereas we confirmed that FHL2 has an antihypertrophic role, our data suggest that FHL2 genetic variants did not release this antihypertrophic effect of FHL2. Instead, our data support the view that FHL2 genetic variants could increase cardiac function in HCM.

Acknowledgments We are thankful to family members for collaboration. We would like to thank M. Komajda (Paris) for continuous support in the Eurogene Heart Failure network, M. Hirt (Hamburg) for fruitful discussion. We would also like to thank A. Eder, I. Vollert, C. Neuber and A. Stöhr (Hamburg) for help in contractility experiments, E. Kraemer and S. Schlossarek (Hamburg) for isolation of human ventricular RNA, and Charles Redwood (Oxford) for DNA sequencing of human HCM tissue samples. Funding sources: This work was supported by the Leducq Foundation (Eurogene Heart Failure), the seventh Framework Program of the European Union (Health-F2-2009-241577-Big-Heart project), and the Association Institut de Myologie (Paris).

Conflict of interest None.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Ahmad F, Seidman JG, Seidman CE (2005) The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet 6:185–216. doi:10.1146/annurev.genom.6.080604.162132
2. Arimura T, Hayashi T, Matsumoto Y, Shibata H, Hiroi S, Nakamura T, Inagaki N, Hinohara K, Takahashi M, Manatsu SI, Sasaoka T, Izumi T, Bonne G, Schwartz K, Kimura A (2007) Structural analysis of four and half LIM protein-2 in dilated cardiomyopathy. Biochim Biophys Acta 1771:162–167. doi:10.1016/j.bbrc.2007.03.128
3. Barefield D, Sadayappan S (2010) Phosphorylation and function of cardiac myosin binding protein-C in health and disease. J Mol Cell Cardiol 48:866–875. doi:10.1016/j.yjmcc.2009.11.014
4. Bovill E, Westaby S, Crisp A, Jacobs S, Shaw T (2009) Reduction of four-and-a-half LIM-protein 2 expression occurs in human left ventricular failure and leads to altered localization and reduced activity of metabolic enzymes. J Thorac Cardiovasc Surg 137:853–861. doi:10.1016/j.jtcvs.2008.09.006
5. Brown S, McGrath MJ, Ooms LM, Gurung R, Maimone MM, Mitchell CA (1999) Characterization of two isoforms of the skeletal muscle LIM protein 1, SLIM1. Localization of SLIM1 at focal adhesions and the isoform slimmer in the nucleus of myoblasts and cytoplasm of myotubes suggests distinct roles in the cytoskeleton and in nuclear-cytosplasmic communication. J Biol Chem 274:27083–27091
6. Carrier L, Knoll R, Vignier N, Keller DI, Bausero P, Prudhon B, Isnard R, Ambrosine ML, Fiszman M, Ross J Jr, Schwartz K, Chien KR (2004) Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice. Cardiovasc Res 63:293–304. doi:10.1016/j.cardiores.2004.09.008636304001683
7. Cazorla O, Szilagyi S, Vignier N, Salazar G, Kramer E, Vassort G, Carrier L, Lacampagne A (2006) Length and protein kinase a modulations of myocytes in cardiac myosin binding protein C-deficient mice. Cardiovasc Res 69:370–380. doi:10.1016/j.cardiores.2005.11.009
8. Charron P, Dubourg O, Desnos M, Bennaceur M, Carrier L, Camproux AC, Isnard R, Hagège A, Langlard JM, Bonne G, Richard P, Hainque B, Bouhour JB, Schwartz K, Komajda M (1998) Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to cardiac myosin binding protein C gene. Circulation 97:2230–2236
9. Charron P, Dubourg O, Desnos M, Bouhour JB, Isnard R, Hagège A, Carrier L, Bonne G, Tesson F, Richard P, Hainque B, Buzzi JC, Schwartz K, Komajda M (1998) Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in genotyped children. Eur Heart J 19:1377–1382
10. Charron P, Dubourg O, Desnos M, Isnard R, Hagège A, Bonne G, Carrier L, Tesson F, Bouhour JB, Buzzi JC, Feingold J, Schwartz K, Komajda M (1998) Genotype-phenotype correlations in familial hypertrophic cardiomyopathy: a comparison between mutations in the cardiac protein-C and the β-myosin heavy chain genes. Eur Heart J 19:139–145
11. Chu PH, Bardwell WM, Yu G, Ross J, Chen J (2000) FHL2/SLIM3 is not essential for cardiac development and function. Mol Cell Biol 20:7460–7462
12. Chu PH, Chen J (2011) The novel roles of four and a half LIM proteins 1 and 2 in the cardiovascular system. Chang Gung Med J 34:127–134
13. Chu PH, Ruiz-Lozano P, Zhou Q, Cai C, Chen J (2000) Expression patterns of FHL/SLIM family members suggest important functional roles in skeletal muscle and cardiovascular system. Mech Dev 95:259–265. doi:s002547730003415
14. Crocini C, Arimura T, Reischmann S, Eder A, Braren I, Hansen A, Eschenhagen T, Kimura A, Carrier L (2013) Impact of ANKRD1 mutations associated with hypertrophic cardiomyopathy on contraction parameters of engineered heart tissue. Basic Res Cardiol 108:349. doi:10.1007/s00395-013-0349-x
15. Dasgupta T, Stillwagon SJ, Ladd AN (2013) Gene expression analyses implicate an alternative splicing program in regulating contractile gene expression and serum response factor activity in mice. PLoS One 8:e56590. doi:10.1371/journal.pone.0056590
16. De S, Borowski AG, Wang H, Nye L, Xin B, Thomas JD, Tang WH (2011) Subclinical echocardiographic abnormalities in phenotype-negative carriers of myosin-binding protein C gene mutation for hypertrophic cardiomyopathy. Am Heart J 162(262–267):e263. doi:10.1016/j.ahj.2011.05.018
17. Elliott P, Andersson B, Arbusini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kuhl U, Maisch B, McKenna WJ, Monserrat L, Pankuweit S, Raperzzi C, Seferovic P, Tavazzi L, Keren A (2008) Classification of the cardiomyopathies: a position
statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29:270–276. doi:10.1093/eurheartj/hhn342

18. Fraysse B, Weinberger F, Bardsdell SC, Cuello F, Vignier N, Geertz B, Starbatty J, Kramer E, Coirault C, Eschenhagen T, Kentish JC, Avkiran M, Carrier L (2012) Increased myofilament Ca\(^{2+}\)-sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. J Mol Cell Cardiol 52:1299–1307. doi:10.1016/j.yjmcc.2012.03.009

19. Friedrich FW, Bausero P, Sun Y, Treszl A, Kramer E, Juhr D, Richard P, Wegscheider K, Schwartz K, Brito D, Arbustini E, Waldenstrom A, Isnard R, Komajda M, Eschenhagen T, Carrier L, Project EHF (2009) A new polymorphism in human calmodulin III gene promoter is a potential modifier gene for familial hypertrophic cardiomyopathy. Eur Heart J 30:1648–1655. doi:10.1093/eurheartj/ehp153

20. Friedrich FW, Carrier L (2012) Genetics of hypertrophic and dilated cardiomyopathy. Curr Pharm Biotechnol [pii].doi:CPB-123

21. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW, American College of Cardiology Foundation/American Heart Association Task Force on Practice G, American Association for Thoracic S, American Society of A, Heart Rhythm S, Society for Cardiovascular A, American Society of Nuclear C, Heart Failure A, American College of Cardiology Foundation/American Heart Association Task Force on Practice G, American Association for Thoracic S, American Society of A, Heart Rhythm S, Society for Cardiovascular A, American Society of Nuclear C, Heart Failure A (2003) American College of Cardiology/American Heart Association guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 108:2783–2831. doi:10.1161/CIRCULATIONAHA.107.697183

22. Gericke-Bouwkamp C, Behrens-Gawlik V, Reischmann S, Geertz B, Stimpel D, Weinberger F, Schlossarek S, Precigout G, Braren I, Eschenhagen T, Meairini G, Lorain S, Voit T, Dreyfus PA, Garcia L, Carrier L (2013) Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice. EMBO Mol Med 5:1060–1077. doi:10.1002/emmm.201202168

23. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW, American College of Cardiology Foundation/American Heart Association Task Force on Practice G, American Association for Thoracic S, American Society of A, Heart Rhythm S, Society for Cardiovascular A, Interventions, Society of Thoracic S (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation 124:783–831. doi:10.1161/CIR.0b013e318223ed2bd

24. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW, American College of Cardiology Foundation/American Heart Association Task Force on Practice G, American Association for Thoracic S, American Society of A, Heart Rhythm S, Society for Cardiovascular A, Interventions, Society of Thoracic S (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 124:2761–2796. doi:10.1161/CIRCULATIONAHA.110.231823e230

25. Hansen A, Eder A, Bonstrup M, Flato M, Mewe M, Schaaf S, Akeshirioglu B, Schworer A, Uebeler J, Eschenhagen T (2010) Development of a drug screening platform based on engineered heart tissue. Circ Res 107:35–44. doi:10.1161/CIRCRESAHA.109.211458

26. Hirt MN, Sorensen NA, Bartholdt LM, Boeddinghaus J, Schaaf S, Eder A, Vollert I, Stohr A, Schulze T, Witten A, Stoll M, Hansen A, Eschenhagen T (2012) Increased afterload induces pathological cardiac hypertrophy: a new in vitro model. Basic Res Cardiol 107:307. doi:10.1007/s00395-012-0307-z

27. Ho CY, Sweitzer NK, McDonough B, Maron BJ, Casey SA, Seidman JG, Seidman CE, Solomon SD (2002) Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 105:2992–2997

28. Hojavey B, Rothermel BA, Gillette TG, Hill JA (2012) FHL2 binds calcineurin and represses pathological cardiac growth. Mol Cell Biol 32:4025–4034. doi:10.1128/mcb.05948-11

29. Jentzsch C, Leierseder S, Loyer X, Flohrshutz I, Sassi Y, Hartmann D, Thum T, Laggerbauer B, Engelhardt S (2012) A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. J Mol Cell Cardiol 52:13–20. doi:10.1016/j.yjmcc.2011.07.010

30. Johannessen M, Moller S, Hansen T, Moens U, Van Ghelue M (2006) The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell Mol Life Sci 63:268–284. doi:10.1007/s00018-005-5438-z

31. Kimura A (2010) Molecular basis of hereditary cardiomyopathy: abnormalities in calcium sensitivity, stretch response, stress response and beyond. J Hum Genet 55:81–90. doi:10.1038/jhg.2009.138

32. Kong Y, Shelton JM, Rothermel B, Li X, Richardson JA, Bassel-Duby R, Williams RS (2001) Cardiac-specific LIM protein FHL2 modifies the hypertrophic response to beta-adrenergic stimulation. Circulation 103:2731–2738. doi:10.1161/01.CIR.103.22.2731

33. Lange S, Auerbach D, McLaughlin P, Perriard E, Schafer BW, Perriard JC, Ehler E (2002) Subcellular targeting of metabolic enzymes to titin in heart muscle may be mediated by DRAL/FHL-2. J Cell Sci 115:4925–4936

34. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, 3rd, Spirito P, Cate FJ, Wigle ED, American College of Cardiology Foundation Task Force on Clinical Expert Consensus Consensus and the European Society of Cardiology Committee for Practice G (2003) American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 24:1965–1991

35. Meairini G, Stimpel D, Kramer E, Geertz B, Braren I, Gericke-Bouwkamp C, Precigout G, Muller OI, Katus HA, Eschenhagen T, Voit T, Garcia L, Lorain S, Carrier L (2013) Repair of Mybpc3 mRNA by 5’-trans-splicing in a mouse model of hypertrophic cardiomyopathy. Mol Ther Nucleic Acids 2:e102. doi:10.1038/mtna.2013.31

36. Michels M, Soliman OI, Kofflard MJ, Hoedemaekers YM, Dooijes D, Majoer-Krakauer D, ten Cate FJ (2009) Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations. JACC Cardiovasc Imaging 2:58–64. doi:10.1016/j.jcmg.2008.08.003

37. Moore JR, Leinwand LA, Warshaw DM (2012) Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor. Circ Res 111:375–385. doi:10.1161/CIRCRESAHA.110.223842

38. Morimoto S, Yanaga F, Minakami R, Ohtsuki I (1999) Ca\(^{2+}\)-sensitizing effects of the mutations at Ile-79 and Arg-92 of troponin T in hypertrophic cardiomyopathy. Am J Physiol 2731

39. Muller JM, Metzger E, Greschik H, Bosserhoff AK, Mercep L, Buettner R, Schule R (2002) The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus. EMBO J 21:736–748
40. Okamoto R, Li Y, Noma K, Hiroi Y, Liu PY, Taniguchi M, Ito M, Liao JK (2013) FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2. FASEB J 27:1439–1449. doi:10.1096/fj.12-217018

41. Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Salton C, Gibson CM, Udelson JE, O’Donnell C, Lesser JR, Manning WJ, Maron MS (2010) Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 106:261–267. doi:10.1016/j.amjcard.2010.03.020

42. Philippu P, Schratt G, Dieterich C, Muller JM, Galgoczy P, Pohlmann L, Kroger I, Vignier N, Schlossarek S, Kramer E, Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Choe E, Leinwand LA, Ruppel K, Spadich JA (2013) Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human beta-cardiac myosin motor function. Proc Natl Acad Sci U S A 110:12607–12612. doi:10.1073/pnas.1309493110

43. Sommese RF, Sung J, Nag S, Sutton S, Deacon JC, Choe E, Leinwand LA, Ruppel K, Spadich JA (2013) Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human beta-cardiac myosin motor function. Proc Natl Acad Sci U S A 110:12607–12612. doi:10.1073/pnas.1309493110

44. Purcell NH, Darwis D, Bueno OF, Muller JM, Pohlmann L, Kroger I, Vignier N, Schlossarek S, Kramer E, Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Choe E, Leinwand LA, Ruppel K, Spadich JA (2013) Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human beta-cardiac myosin motor function. Proc Natl Acad Sci U S A 110:12607–12612. doi:10.1073/pnas.1309493110

45. Robinson PA, Brown S, McGrath MJ, Coghill ID, Gurung R, Robinson P, Griffiths PJ, Watkins H, Redwood CS (2007) Dilated cardiomyopathy: Robert L. Frye Lecture. Mayo Clin Proc 77:1315–1319. doi:10.4065/77.12.1315

46. Robinson PA, Brown S, McGrath MJ, Coghill ID, Gurung R, Robinson P, Griffiths PJ, Watkins H, Redwood CS (2007) Dilated cardiomyopathy: Robert L. Frye Lecture. Mayo Clin Proc 77:1315–1319. doi:10.4065/77.12.1315

47. Robinson PA, Brown S, McGrath MJ, Coghill ID, Gurung R, Robinson P, Griffiths PJ, Watkins H, Redwood CS (2007) Dilated cardiomyopathy: Robert L. Frye Lecture. Mayo Clin Proc 77:1315–1319. doi:10.4065/77.12.1315

48. Schaaf S, Shibamiya A, Mewe M, Eder A, Stohr A, Hirt MN, Rauh T, Zimmermann WH, Conradi L, Eschenhagen T, Carrier L, Boontje NM, Kuster DW, van Slegtenhorst M, van der Velden J (2009) Cardiac myosin-binding protein c is required for complete relaxation in intact myocytes. Circ Res 105:239–248. doi:10.1161/CIRCRESAHA.108.185552

49. Schaaf S, Shibamiya A, Mewe M, Eder A, Stohr A, Hirt MN, Rauh T, Zimmermann WH, Conradi L, Eschenhagen T, Carrier L, Boontje NM, Kuster DW, van Slegtenhorst M, van der Velden J (2009) Cardiac myosin-binding protein c is required for complete relaxation in intact myocytes. Circ Res 105:239–248. doi:10.1161/CIRCRESAHA.108.185552

50. Scholl FA, McLoughlin P, Ehler E, de Giovanni C, Schafer BW, Tardiff JC, Hewett TE, Palmer BM, Olsson C, Factor SM, Moore RL, Robbins J, Leinwand LA (1999) Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy. J Clin Invest 104:469–481. doi:10.1172/JCI6067

51. Sequeira V, Wijnker PJ, Nijenkamp LL, Kuster DW, Najafi A, Witjas-Paalberends ER, Regan JA, Boontje N, Ten Cate FJ, Germans T, Carrier L, Sadayappan S, van Slegtenhorst MA, Zaremba R, Foster DB, Murphy AM, Poggesi C, Dos Remedios C, Stienen GJ, Ho CY, Michels M, van der Velden J (2013) Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations. Circ Res 112:1491–1505. doi:10.1161/CIRCRESAHA.111.300436

52. Tardiff JC, Hewett TE, Palmer BM, Olsson C, Factor SM, Moore RL, Robbins J, Leinwand LA (1999) Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy. J Clin Invest 104:469–481. doi:10.1172/JCI6067

53. Tardiff JC, Hewett TE, Palmer BM, Olsson C, Factor SM, Moore RL, Robbins J, Leinwand LA (1999) Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy. J Clin Invest 104:469–481. doi:10.1172/JCI6067

54. Vignier N, Schlossarek S, Frayse B, Meanari G, Kramer E, Poitou H, Mougnet N, Guiard J, Reimer R, Hohenberg H, Schwartz K, Vernet M, Eschenhagen T, Carrier L (2009) Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyocytes. Biochem J 457:451–461. doi:10.1042/BJ20131026

55. Vignier N, Schlossarek S, Frayse B, Meanari G, Kramer E, Poitou H, Mougnet N, Guiard J, Reimer R, Hohenberg H, Schwartz K, Vernet M, Eschenhagen T, Carrier L (2009) Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyocytes. Biochem J 457:451–461. doi:10.1042/BJ20131026

56. Vignier N, Schlossarek S, Frayse B, Meanari G, Kramer E, Poitou H, Mougnet N, Guiard J, Reimer R, Hohenberg H, Schwartz K, Vernet M, Eschenhagen T, Carrier L (2009) Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyocytes. Biochem J 457:451–461. doi:10.1042/BJ20131026

57. Vignier N, Schlossarek S, Frayse B, Meanari G, Kramer E, Poitou H, Mougnet N, Guiard J, Reimer R, Hohenberg H, Schwartz K, Vernet M, Eschenhagen T, Carrier L (2009) Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyocytes. Biochem J 457:451–461. doi:10.1042/BJ20131026

58. Vignier N, Schlossarek S, Frayse B, Meanari G, Kramer E, Poitou H, Mougnet N, Guiard J, Reimer R, Hohenberg H, Schwartz K, Vernet M, Eschenhagen T, Carrier L (2009) Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyocytes. Biochem J 457:451–461. doi:10.1042/BJ20131026